PEACE (PEdiatric Antifungal Comparative Effectiveness) 

IPFN Study 005: Comparative Effectiveness of Treatments of Pediatric Candidemia (NCT01869829)

Enrollment Completed, Analysis Ongoing

PEACE was a multi-center (US and international sites), prospective observational comparative-effectiveness study. The primary aim of the study was to compare the effectiveness of echinocandin versus amphotericin B or triazole antifungal therapy for pediatric invasive candidiasis and invasive candidemia. The study collected data on 750 events of proven/probably invasive candidiasis in children and adolescents. 

 

The IPFN has multiple ongoing research projects dedicated to improving the diagnosis, treatment, and outcomes of pediatric patients with invasive fungal infections. 

 

 

 

 

 

 

 

 

 

 

PEACE Study

BIOPIC (BIOmarkers for Pediatric Invasive Candidiasis)

IPFN Study 006: Evaluation of Fungal Biomarkers for Diagnosis of Pediatric Candidemia (NCT02220790)

Currently Enrolling

This study will determine if fungal biomarkers can improve the time to diagnosis of invasive candidiasis in high risk pediatric patients as compared to traditional blood cultures.  Additionally, these same fungal biomarkers will be evaluated to measure response to antifungal treatment in those high risk patients that develop invasive candidiasis. 

 

We will prospectively enroll 500 patients throughout all International Pediatric Fungal Network (IPFN) sites over 4 years.  In order to increase the utility of these biomarkers, we will only enroll pediatric patients who are at “high-risk” for developing candidiasis (defined in inclusion criteria below, and based on previous epidemiologic studies).  When an eligible patient has a blood culture drawn for clinical care, he or she will be enrolled and have research blood for biomarker testing drawn as soon as possible. The day that the clinical blood culture is drawn is "Day 0".

 

Most patients will not go on to develop invasive candidiasis, as defined by the international Mycoses Study Group / European Organization for the Treatment of Cancer (MSG/EORTC) definitions, and will not have any more blood drawn in this study.  For those patients that do develop invasive candidiasis, we will also potentially draw study blood for the same biomarker tests on days +5, +7, and +14.  This equates to 5, 7, and 14 days after “Day 0”. 

Blood for biomarkers will be drawn from patients using the kits and tubes provided by the IPFN. 

 

Inclusion Criteria for initial study enrollment

  • Males or females age > 120 days and <18 years  
  • Have at least one of the following conditions:
    • ​admitted to a non-neonatal ICU with any underlying disease
    • being imminently transferred to a non-neonatal ICU with any underlying disease
    • gastro-intestinal insufficiency (e.g., chronic short-gut syndrome) and admitted to anywhere in the hospital
    • hematologic malignancy (limited to AML, ALL, Non-Hodgkin’s lymphoma, and myelodysplastic syndrome) and admitted to anywhere in the hospital
    • solid tumor malignancy and admitted to anywhere in the hospital
    • hematopoietic stem cell or bone marrow transplant and admitted to anywhere in the hospital
    • aplastic anemia and admitted to anywhere in the hospital
  • Have ≥ 1 blood culture drawn for clinical concern of infection at time of enrollment
  • Have ≥ 1 central catheter (arterial or venous)
  • Clinician initiates and/or changes any systemic antimicrobial therapy at the time of enrollment
  • Parental/guardian permission (informed consent) and, if appropriate, child assent 

Inclusion criteria for subsequent research blood samples:  

  • Patient meets all criteria for initial enrollment, has the initial study blood sample collected, AND is diagnosed with invasive candidiasis according to the international definitions between day 0 and day +14 

Exclusion Criteria

  • Diagnosis of possible, probable or proven invasive fungal infection within the 30 days prior to study enrollment
  • Previous inclusion in this study
  • Weight < 4 kg (Due to constraints of no more than 3 ml/kg of blood to be drawn over an 8 week period). Subjects that fall below 4 kg during the study period will not have more than 0.75 ml/kg of blood drawn each time.
  • Patient receiving empiric antifungal therapy for prolonged neutropenia or fever that was started prior to the time that the clinically indicated blood culture was drawn.
  • If blood cultures are obtained and anti-infectives are added/changed ONLY as part of a local protocol and not driven by clinical concern for infection.

BIOPIC Study

International Pediatric Fungal Network, Box 3499, Duke University Medical Center, Durham, NC 27710. USA.   Tel: 919-668-4847 Email: PFNContracts@duke.edu

Information about additional clinical trials for pediatric fungal infections can be found on ClinicalTrials.gov.